- Venous thrombosis is significant cause of morbidity and mortality
- Pulmonary embolus accounts for 10 - 25 % of hospital deaths
- At least 20% patients with a DVT develop a post-thrombotic limb
- Most calf DVTs are clinically silent
- 80% of calf DVTs lyse spontaneously without treatment
- 20% of calf DVTs propagate to the thigh and have increased risk of
PE
Pathophysiology
- Thrombus formation and propagation depends on the presence of
Virchow's triad
- Venous stasis
- Hypercoagulable state
- Endothelial damage
- Immobility contributes to venous stasis
- Endothelial damage can result from external compression
- A hypercoagulable state can be due to drugs or malignancy
Risk factors for venous thrombosis
| Patient Factors |
Disease or surgical procedure |
| Age |
Trauma or surgery esp. pelvis, hip, lower limb |
| Obesity |
Malignancy |
| Varicose veins |
Heart failure |
| Immobility |
Recent myocardial infarction |
| Pregnancy |
Lower limb paralysis |
| Puerperium |
Infection |
| High-dose oestrogen therapy |
Inflammatory bowel disease |
| Previous DVT or PE |
Nephrotic syndrome |
| Thrombophilia: |
Polycythaemia |
| Antithrombin III deficiency |
Paraproteinaemia |
| Protein C deficiency |
Paroxysmal nocturnal haemoglobinuria |
| Protein S deficiency |
Behcet's disease |
| Antiphospholipid antibody |
Homocystinuria |
| Lupus anticoagulant |
|
- It is estimated that about 1:250 of the population have a congenital
thrombophilia
- Potential for venous thrombosis can be investigated by a
thrombophilia screen
- FBC and blood film
- >Clotting studies - APPT / PT / TT
- Reptilase test
- Protein C & S and Antithrombin III assay
- Lupus anticoagulant
Epidemiology of DVT and
pulmonary embolus
|
Calf DVT |
Proximal DVT |
Fatal PE |
| Low risk group |
<10% |
<1% |
0.01% |
| Moderate risk group |
10-40% |
1-10% |
0.1-1% |
| High risk group |
40-80% |
10-30% |
1-10% |
Risk of venous thrombosis during surgery
- Low risk
- Minor surgery (<30 min) + no risk factors other than age
- Major surgery (> 30 min) , age <40 yrs + no other risk factors
- Minor trauma or medical illness
- Moderate risk
- Major general, urological, gynaecological, cardiothoracic,
vascular or neurological surgery + age >40 yrs or other risk factor
- Major medical illness or malignancy
- Major trauma or burn
- Minor surgery, trauma or illness in patients with previous DVT, PE
or thrombophilia
- High risk
- Fracture or major orthopaedic surgery of pelvis, hip or lower limb
- Major pelvic or abdominal surgery for cancer
- Major surgery, trauma or illness in patient with previous DVT, PE
or thrombophilia
- Major lower limb amputation
Prevention of thromboembolism
Prevention of stasis
- Early mobilisation
- Graduate compression stockings
- Intermittent pneumatic compression (e.g. Flowtron boots)
Pharmacologically reduce hypercoagulable state
Heparin
- Acidic mucopolysaccharide
- Unfractionated heparin (MW =
15 kDa)
- Low Molecular Weight Heparin (MW
= 5 kDa)
- Both potentiate Antithrombin III by inactivating activated clotting
factors
- Unfractionated heparin
anti-Xa activity = anti IIa activity
- Low Molecular Weight Heparin anti-Xa activity 4x > than anti IIa activity
- Does not have significant effect on APPT
- Side effects of unfractionated Heparin
- Osteoporosis
- Idiosyncratic thrombocytopenia
Warfarin
- Coumarin derivative & vitamin K antagonist
- Inhibits vitamin K dependent post translational carboxylation of
factors II, VII, IX & X
- Graduated compression stockings reduce incidence of DVT by 50%
- No proven benefit of thigh-length compared to calf-length stockings
- Unfractionated and low molecular weight heparin are equally
effective
- Reduce DVTs by 70% and PEs by 50%
- Unfractionated heparin usually given 5000u 3x daily
- Low Molecular Weight Heparin - Enoxaparin 20 or 40 mg daily
New drugs
- New drugs useful in DVT prophylaxis include
- Thrombin inhibitors (e.g. hirudin)
- Specific factor Xa inhibitors (e.g. fondaparinux)
- Factor Xa inhibitors may be more effective than LMWH
THRIFT recommendations
Current recommendations for DVT prophylaxis
- All hospital inpatients
- Should be assessed for clinical risk factors and overall risk of
thromboembolism
- Should receive prophylaxis according to degree of risk
- Prophylaxis should continue until discharge
- Low risk patients should be mobilised early
- Moderate risk patients should receive specific prophylaxis
NICE Guidelines (2007)
Information and assessment
- Assess patients for individual risk of venous thromboembolism
- Advice patients to stop taking OCP for 4 weeks prior to elective
surgery
- Inform patients that immobility (travel of more than 3 hours) in the
4 weeks before or after surgery increases risk
- Before surgery give verbal and written information on:
- Risk of DVT
- Effectiveness of prophylaxis
- As part of each patient's discharge plan give information on
- Signs and symptoms of DVT
- Correct use of prophylaxis at home
- Implications of not using prophylaxis
Mechanical prophylaxis
- Unless contraindicated, offer all inpatients thigh-length
compressions stockings
- The stocking profile should be
- 18 mmHg at the ankle
- 14 mmHg at the mid-calf
- 8 mmHg at the upper thigh
- Staff should be trained in the use and fitting of the stockings
- Stockings should be worn from the time of admission until the
resumption of normal mobility
- Intermittent pneumatic compression devices should also be used
Pharmacological prophylaxis
- Patients at increased risk of DVT should be offered LMWH
- The risks and benefits of stopping anticoagulation or anti-platelet
therapy should be considered
- Careful planning of the timing of prophylaxis should be given in
those undergoing regional anaesthesia
Other strategies
- Do not allow patients to become dehydrated whilst in hospital
- Consider regional anaesthesia if appropriate
- Consider vena caval filters if patient has existing or recent DVT
- Encourage early mobilisation
Clinical features of DVT
- Clinical presentation of a DVT can be very non-specific
- Many are asymptomatic
- Clinical features depends on site of venous occlusion
- Classical clinical features of a calf DVT are:
- Calf pain and tenderness
- Pyrexia
- Persistent tachycardia
- Homan's sign = pain on passive dorsiflexion of the ankle is a
non-specific sign
- Occlusion of the ileo-femoral vein can result in venous gangrene
(phlegmasia cerulea dolens)

Picture provided by Chris Malkin, Leeds General
Infirmary, Leeds, United kingdom
Investigation of suspected DVT
- Less than 50% of those suspected of having DVT have clot identified
on imaging
D-dimers
- A fibrin degradation product that can be assayed in plasma
- Levels raised in the presence of recent thrombus
- A negative result almost excludes the presence of venous thrombosis
- Decision to proceed to venography or ultrasound often based on
D-dimer result
Venography
- Gold standard
- Will identify both calf vein and proximal thrombus
- Painful and time consuming investigation.
- 2-3% of patients develop contrast reaction
Ultrasound
- Technique has three components - all operator dependent.
- Venous compressibility
- Detection of Doppler flow
- Visualisation of clot
- In femoro-popliteal segment - sensitivity = 94%. specificity = 100%
- In calf veins - sensitivity = 73%. specificity = 86%
- Able to exclude femoro-popliteal or major calf DVT in symptomatic
patients
Treatment of venous thrombosis
- Aims of treatment:
- Prevention of pulmonary embolus
- Restore venous and valvular function to prevent the post
thrombotic limb
- Few aspects of treatment submitted to RCTs
Anticoagulation
- Main component of treatment
- Initially with unfractionated or low molecular weight heparin
- Followed by oral anticoagulation
- LMWHs have increased bioavailability and linear kinetics
- The treatment of isolated calf DVTs is of unproven benefit
- Optimal duration of treatment unknown
- No proof that treatment beyond 3-6 months is required
Surgical thrombectomy
- Considered in massive ileo-femoral thrombosis associated with
phlegmasia cerulea dolens
- Good early results with 62% complete and 38% partial clearance of
ileo-femoral segment
- Unfortunately re-occlusion common
- Thrombolysis of unproven benefit
Pulmonary embolism
- Accounts for 3% of hospital inpatients deaths
- Untreated has a mortality of 30%
- Treated mortality reduced to about 2%
- Only 10% have clinical signs of a DVT
Clinical presentation
| Symptoms |
Signs |
| Dyspnoea |
Low grade pyrexia |
| Pleuritic chest pain |
Central cyanosis |
| Haemoptysis |
Tachycardia |
|
Tachypnoea |
|
Hypotension |
|
Neck vein distension |
|
Pleural rub |
|
Increased pulmonary second sound |
Investigations of possible pulmonary embolus
- Arterial blood gases - hypoxia, hypocarbia but may be normal
- ECG - Signs of right heart strain - classically S1Q3T3
- CXR - Show oligaemia and central pulmonary markings and excludes
other pathologies
- Ventilation / Perfusion scanning - May confirm or refute diagnosis
- Pulmonary angiography and echocardiography useful if haemodynamic
instability
- Spiral CT might replace pulmonary angiography
- Lower limb investigations for DVT as above

Management of pulmonary embolus
- Depends on degree of suspicion and haemodynamic stability
- If high degree of suspicion but stable:
- Anti-coagulate with heparin or LMWH
- Oxygen, analgesia, colloid to increase CVP
- Warfarinise for at least 3 months
- If haemodynamically unstable:
- Consider pulmonary thrombolysis via pulmonary artery catheter
- If thrombolysis contraindicated consider pulmonary embolectomy
Inferior vena caval filters
- Inserted percutaneously usually via femoral vein
- Present a physical barrier to emboli
- Indicated if:
- Recurrent pulmonary emboli despite adequate anti-coagulation
- Extensive proximal venous thrombosis and anticoagulation is
contraindicated
Bibliography
Agu O,
Hamilton G, Baker D. Graduated compression stockings in the prevention of venous
thromboembolism.
Br J Surg 1999; 86:
992-1004.
Bergqvist D. Lowe molecular weight heparin
for the prevention of venous thromboembolism after abdominal surgery.
Br J Surg 2004; 91: 965-974.
Bergqvist D.
Prevention of venous thromboembolism after surgery: a review of
enoxaparin.
Br J Surg 1992; 79:
495-498.
Grace R,
Hunt B J.
Thromboprophylaxis.
Br J Hosp Med 1993; 49: 720-726.
Goldhaber S Z. Pulmonary embolism.
Lancet 2004; 363: 1295-1305
Hampton K K. Pathophysiology of venous
thromboembolism. Hosp Med 2001; 62: 675-672.
Jorgensen L N,
Willie-Jorgensen P, Hauch O.
Prophylaxis of postoperative thromboembolism with low molecular
weight heparins.
Br J Surg 1993; 80:
689-704.
Lensing A W A,
Prandoni P, Prins M H,
Buller H R. Deep vein
thrombosis.
Lancet 1999; 353: 479-485.
Menon K V,
Insall R L, Ignotus P
I. Inferior vena caval
filter: an overview of
current use.
Hosp Med 1998;
59: 224-226.
Mills T D, Chan O, Matson M. The
use of vena caval filters. Hosp Med 2001; 62: 327-331.
Mismetti P, Laporte S, Darmon J-Y,
Buchmuller A, Decousus H. Meta-analysis of low molecular
heparin in the prevention of venous thromboembolism in general surgery.
Br J Surg 2001; 88: 913-930.
Sissons G R J.
Investigation of suspected lower limb venous thrombosis.
Ann R Coll Surg Eng 1998;
80: 49 –54.
Tai N R M,
Atwal A S, Hamilton G.
Modern management of pulmonary embolism.
Br J Surg 1999;
86: 853-868.
Thromboembolic Risk Factors (THRIFT) Consensus
Group. Risk of and
prophylaxis for venous thromboembolism in hospital patients.
Br Med J 1992; 305:
567-574.
Turpie A G G, Chin B S P, Lip G Y H.
Venous thromboembolism: pathophysiology, clinical features and
prevention. Br Med J 2002: 325: 887-890.
Walker I D, Greaves M, Preston F E.
Guidelines: Investigation and management of heritable thrombophilia.
Br J Haematol 2001; 114: 512-528.
Weinmann E E,
Salzman E W. Deep-Vein
Thrombosis.
N Eng J Med 1994; 331: 1630-1641.
Wood M K, Spiro S G. Pulmonary
embolism: clinical features and management. Hosp Med
2000: 61: 46-50. |